OLIPASS Valuation

Is A244460 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A244460 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A244460's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A244460's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A244460?

Key metric: As A244460 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A244460. This is calculated by dividing A244460's market cap by their current revenue.
What is A244460's PS Ratio?
PS Ratio	3.9x
Sales	₩5.25b
Market Cap	₩20.62b

A244460 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.8x
Enterprise Value/EBITDA	-1.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A244460's PS Ratio compare to its peers?

The above table shows the PS ratio for A244460 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	10.8x
A352770 Clinomics	1.9x	n/a	₩18.3b
A086060 GeneBioTech Ltd	0.4x	n/a	₩29.5b
A318160 Cell Bio Human TechLtd	1.1x	n/a	₩31.0b
A298060 SCM Lifescience	39.8x	n/a	₩35.4b
A244460 OLIPASS	3.9x	n/a	₩20.6b

Price-To-Sales vs Peers: A244460 is good value based on its Price-To-Sales Ratio (3.9x) compared to the peer average (10.8x).

Price to Sales Ratio vs Industry

How does A244460's PS Ratio compare vs other companies in the KR Biotechs Industry?

27 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.8x	34.4%
A244460 OLIPASS	3.9x	n/a	US$14.80m
A006280 GC Biopharma	0.9x	8.8%	US$1.07b
A096530 Seegene	2.7x	14.5%	US$734.93m

27 Companies		Estimated Growth	Market Cap
Industry Avg.	8.8x	66.0%
A244460 OLIPASS	3.9x	n/a	US$14.80m

No more companies

Price-To-Sales vs Industry: A244460 is good value based on its Price-To-Sales Ratio (3.9x) compared to the KR Biotechs industry average (8.8x).

Price to Sales Ratio vs Fair Ratio

What is A244460's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A244460 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A244460's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩273,500.00

0.9%

75.3%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,260.00

-5.8%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,200.00

1.7%

-39.0%